Aug 15, 2023 / 06:00PM GMT
Danielle Joy Antalffy - UBS Investment Bank, Research Division - Analyst
All right. Good morning, everyone. My name is Danielle Antalffy, the medtech analyst here at UBS. And we are very lucky to have with us on this very exciting fireside chat the Johnson & Johnson Biosense Webster team. We are represented in full force here. Celine Martin, the company Group Chairman of CSS. Sorry, I guess, more than just Biosense Webster. We have Jasmina Brooks, the President of Biosense Webster; and Anthony Hong, VP Preclinical and Clinical Research and Medical Affairs. I know it's probably up there.
But anyway, thank you, guys, for joining. It's a very exciting time in electrophysiology and a lot is happening and a lot is going to happen over the next few months.
Questions and Answers:
Danielle Joy Antalffy - UBS Investment Bank, Research Division - AnalystSo maybe let's get a start, level setting. Biosense Webster is the very clear market leader today in electrophysiology. Can you talk, Celine, about how the EP market has evolved over the last decade?
Trustpilot
